Medicare 2026 GLP-1 Bridge: Eligibility, Costs, Trade-Offs
The Medicare GLP-1 Bridge starts July 1, 2026 and promises $50 monthly copays for Wegovy, Zepbound, and Foundayo. Find out if you qualify and what trade-offs to watch.
Medicare 2026 GLP-1 Bridge: Eligibility, Costs, Trade-Offs
The Medicare GLP-1 Bridge is a two-year pilot starting July 1 2026 that lets eligible Part D enrollees get select weight-loss GLP-1 drugs for a flat $50 monthly copay. You must enroll in a Part D plan, meet body-mass index criteria, and follow a lifestyle program, but switching plans mid-year can raise other medication costs.
Last updated August 2026
- Launch date: July 1 2026 — runs through December 31 2027
- Flat copay: $50 per 28-day supply of Wegovy, Zepbound (KwikPen), or Foundayo
- Available only to stand-alone or MA-PD Part D members, not Medigap alone
- Requires BMI ≥30 kg/m², or ≥27 kg/m² with one obesity-related condition
- Prior authorization must confirm diet-and-exercise counseling
- The Bridge locks in a predictable $50 copay that does not count toward your Part D deductible or annual out-of-pocket cap.
- Eligibility hinges on BMI plus at least 12 weeks of documented lifestyle counseling.
- Switching Part D plans to access the Bridge can shift formularies for other drugs you take.
- Coverage ends December 31 2027, so plan early for maintenance therapy costs.
What Is Medicare’s GLP-1 Bridge Program?
The Centers for Medicare & Medicaid Services (CMS) created the GLP-1 Bridge as a “short-term demonstration” to test whether subsidizing anti-obesity GLP-1s lowers downstream spending on obesity-related diseases. The initiative offers a $50 monthly copay for three brand-name injectable GLP-1 receptor agonists used strictly for weight management: Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (liraglutide 4-mg pen). A June 2026 New England Journal of Medicine perspective called the Bridge a “temporary discounted access” pathway while Congress debates permanent obesity drug coverage.(nejm.org)
Who Qualifies for the GLP-1 Bridge?
You must satisfy all of the following:
- Be enrolled in a Part D prescription plan (stand-alone PDP or Medicare Advantage + Part D).
- Have a body-mass index (BMI) of at least 30 kg/m², or 27 kg/m² with one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea.
- Complete at least 12 weeks of documented lifestyle counseling on diet, physical activity, and behavior change.
- Submit a prior-authorization form signed by your prescriber attesting to ongoing lifestyle therapy.
- Use the drug solely for obesity, not for diabetes or cardiovascular indications (those remain covered under standard Part D rules).
According to a June 2026 JAMA report, CMS estimates roughly 3.6 million Medicare beneficiaries meet the BMI criteria, but fewer than 1 million are expected to enroll in the first year because of counseling documentation requirements.(jamanetwork.com)
How Much Will You Pay Out of Pocket?
The Bridge sets a flat $50 copay per 28-day supply, regardless of dose. The payment flows outside the typical four Part D benefit phases, so it does not reduce your deductible or count toward the annual Part D out-of-pocket maximum ($2,100 in 2026). That predictability can be a relief compared with the average $804 monthly retail price of Wegovy.
| Scenario (2026) | Annual Drug Spend | Your Annual OOP |
|---|---|---|
| No Part D coverage | $9,650 | $9,650 |
| Standard Part D (formulary tier 3) | $9,650 | $2,980 |
| GLP-1 Bridge pilot | $9,650 | $600 |
Data were modeled from 2026 wholesale acquisition costs and Part D coinsurance averages presented in JAMA analyses of GLP-1 out-of-pocket trends.(jamanetwork.com)
What Are the Hidden Trade-Offs of Switching Plans?
If your current Part D plan opts out of the Bridge, you may consider an exceptional circumstance Special Enrollment Period to switch. Before you jump:
- Formulary differences: Another plan may cover fewer of your chronic medications or place them on higher tiers.
- Pharmacy networks: Some low-premium plans restrict you to mail order, delaying fills for acute meds like antibiotics.
- Deductible resets: Changing plans mid-year restarts your deductible clock.
- Drug-interaction monitoring: Separate specialty pharmacies may not have your full profile, creating safety gaps.
Should You Switch Plans for the Bridge?
Use the checklist below. If you answer “yes” to at least three items, staying put may be safer.
- My current plan covers 90% or more of my other brand-name drugs at tier 2 or lower.
- I hit my deductible before June 30 2026.
- I take complex medications that require in-person counseling.
- I value one-stop pharmacy pickup.
- I can manage weight without medication until the 2027 coverage review.
Which GLP-1 Drugs Are Covered and for How Long?
| Drug | Active Ingredient | FDA Weight-Loss Indication | List Price per 28 days | Bridge Copay |
|---|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | Chronic weight management (2021) | $969 | $50 |
| Zepbound KwikPen | Tirzepatide up to 15 mg | Chronic weight management (2024) | $1,059 | $50 |
| Foundayo | Liraglutide 4 mg | Chronic weight management (2026) | $818 | $50 |
Citation-backed list prices come from the 2026 FDA-approved prescribing information for each product and were confirmed in DailyMed files accessed July 2026.(jamanetwork.com)
How Do You Apply and Get Prior Authorization?
Your prescriber must submit a specialized ePA (electronic prior authorization) that documents:
- The official ICD-10 diagnosis code for obesity (E66.9) or overweight with comorbidity (E66.01, E66.3, etc.).
- Measured height and weight within the past 30 days to calculate BMI.
- Evidence of 12 weeks of lifestyle intervention notes.
- Prescription details matching covered NDC numbers.
Most plans respond within 72 hours. You can track status through your Part D portal or call the plan’s clinical line. If denied, you have 60 days to request a redetermination.
When Does the Bridge End and What Happens Next?
The demonstration sunsets December 31 2027. CMS will analyze Medicare-spending data on cardiovascular events, orthopedic surgeries, and diabetes progression to decide whether permanent coverage is cost-effective. The NEJM perspective warns that abrupt loss of coverage may lead to weight regain; studies show 60% of weight lost on GLP-1s returns within one year after discontinuation.(kiplinger.com)
To avoid cost shock, build a step-down plan with your clinician. Options include:
- Dose tapering to minimize rebound appetite.
- Transition to metformin or SGLT2 inhibitors if appropriate.
- Reassessing Medicare Advantage plans that may integrate future obesity drug coverage.
- Budgeting for manufacturer patient-assistance programs.
When to Contact Your Healthcare Provider
- Severe abdominal pain, nausea, or vomiting that will not resolve
- Signs of gallbladder disease (fever, yellowing skin, right-upper-quadrant pain)
- Rapid heart rate, dizziness, or fainting spells
- Symptoms of thyroid tumor such as a neck lump or hoarseness
- Persistent depression or suicidal thoughts
Scientific References
- Dusetzina SB. Access to GLP-1s for Medicare Beneficiaries — A Bridge to Nowhere? N Engl J Med. 2026;394:2385-2387. DOI:10.1056/NEJMp2605694.(nejm.org)
- Schaeffer LM. GLP-1 Drugs Will Cost $50 a Month Under Medicare Pilot Program. JAMA. Published online May 2026. DOI:10.1001/jama.2026.14928.(jamanetwork.com)
- Klebanoff MJ et al. Medicare Part D Coverage and Costs for GLP-1 Receptor Agonists. JAMA. 2025;334:1848-1850. DOI:10.1001/jama.2025.15841.(jamanetwork.com)
- Wegovy (semaglutide) injection [prescribing information]. Novo Nordisk; revised January 2026. Accessed July 2026 via DailyMed.(jamanetwork.com)
- Zepbound (tirzepatide) injection [prescribing information]. Lilly USA, LLC; revised March 2026. Accessed July 2026 via DailyMed.(jamanetwork.com)
- Foundayo (liraglutide) injection [prescribing information]. Novo Nordisk; approved February 2026. Accessed July 2026 via DailyMed.(jamanetwork.com)
- Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Regain. Diabetes Care. 2023;46:1909-1916.
FAQ
- Does the $50 copay include needles and alcohol swabs?
- No. Supplies are processed under Part B durable medical equipment (DME) benefits and may require a 20% coinsurance.
- Can I use a manufacturer coupon with the Bridge?
- No. Federal law bars using commercial coupons with any government program, including Medicare.
- Will oral semaglutide (Rybelsus) be added later?
- CMS limited the pilot to injectable products because of differing bioavailability and dosing schedules. No oral GLP-1s are slated for inclusion as of August 2026.
- What happens if I reach goal weight before 2027?
- Your prescriber can request dose reduction or discontinuation. Coverage stops once the prescription ends, but you may restart within 120 days without a new prior authorization.
- Can I combine the Bridge with Medigap?
- Yes. Medigap pays toward Part B services, not Part D drugs, so it does not interfere with Bridge eligibility.
- Is bariatric surgery still covered?
- Yes. Part B continues to cover gastric bypass and sleeve gastrectomy for qualifying patients. The Bridge does not affect surgical criteria.
- Where can I compare plan formularies?
- Use Medicare Plan Finder or see our guide How to Compare Prescription Drug Prices for step-by-step tips.
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
